Gilead Sciences (GILD) FAQ

Gilead Sciences (GILD) currently reports a PEG ratio of 8.76. That is above the Healthcare sector average of 4.93. Use the charts on this page to explore Gilead Sciences's PEG ratio history and peer comparisons.

Gilead Sciences's PEG ratio of 8.76 is higher than the Healthcare sector average of 4.93. That is roughly 77.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The PEG ratio is a valuation multiple that relates Gilead Sciences's market price to a fundamental measure such as earnings, sales, or book value. At 8.76, GILD can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current PEG ratio of 8.76, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 4.93. From there, open related valuation or income-statement pages for Gilead Sciences, and consider following GILD for alerts when major investors trade the stock.

Gilead Sciences is classified in the Healthcare sector. On PEG ratio, it currently shows 8.76 versus a sector average near 4.93. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GILD with unrelated industries.